Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

European Psychiatry : the Journal of the Association of European Psychiatrists
Haya Ascher-SvanumDavid McDonnell

Abstract

Adding another antipsychotic to a treatment regimen was previously used in evaluating the medication's efficacy. Supplementation of depot antipsychotics with oral antipsychotics is particularly meaningful because depot formulations are typically chosen for patients struggling with adherence to oral antipsychotics. This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine. We used 12 months of data from an open-label, single-arm extension study of patients with schizophrenia or schizoaffective disorder (N=931) treated with olanzapine-LAI. The prevalence, duration, time to first supplementation, and best predictors of oral supplementation were assessed. Oral supplementation occurred in 21% of patients for a median of 31 days with mean modal dose of 10.8 mg/day. Mean time to first supplementation was shorter for patients who were at least moderately ill at baseline compared to less ill patients (47 vs. 97 days, p<0.001). Best predictors of oral supplementation included a more severe illness profile at baseline, lower olanzapine-LAI dose prior to oral supplementation, supervised living arrangements, and being African-American. Supplementation of olanzapine-LAI appears ...Continue Reading

References

Apr 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R BarnesM Patel
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
May 1, 1994·Drugs·J M DavisL ] Metalon L [corrected to Matalon
Feb 7, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M KaneN R Schooler
May 9, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·J A Cramer, R Rosenheck
Sep 24, 1999·Current Medical Research and Opinion·A Kalali
Apr 12, 2003·British Journal of Clinical Pharmacology·Norio Yasui-FurukoriTomonori Tateishi
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Toshiaki AoshimaKoichi Otani
Jun 5, 2003·The American Journal of Psychiatry·John M KaneKeith Karcher
Aug 5, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Peter J WeidenJulie Locklear
Sep 1, 2004·The American Journal of Psychiatry·Theodore J Wilf
Jun 29, 2005·Schizophrenia Research·Stefan LeuchtRolf R Engel
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
May 3, 2006·The Journal of Clinical Psychiatry·Haya Ascher-SvanumJeff W Swanson
Oct 20, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jean-Pierre LindenmayerStuart Kushner
May 2, 2007·Schizophrenia Bulletin·Mark OlfsonHaya Ascher-Svanum
Dec 21, 2007·Schizophrenia Bulletin·Joyce C WestMark Olfson
Mar 4, 2008·The Journal of Clinical Psychiatry·Michael R LawAlyce S Adams

❮ Previous
Next ❯

Citations

Sep 29, 2015·Journal of Medical Economics·Thomas R EinarsonBasil G Bereza
Nov 28, 2013·Nordic Journal of Psychiatry·Thomas R EinarsonMichiel E H Hemels
Aug 10, 2013·The Australian and New Zealand Journal of Psychiatry·Majella Su-Xian ChewBirinder Narang
Jan 29, 2021·The Mental Health Clinician·Trevor A StumpRoger W Sommi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here